The SUNRISE trial underscores eptinezumab’s preventive efficacy and consistent tolerability profile in a largely Asian chronic migraine population, filling a critical data gap in global neurology care.
Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the first 4 weeks, compared to placebo.
At EAN 2025, Lundbeck presented new results from the SUNRISE trial (NCT04921384), a pivotal Phase III randomized, placebo-controlled study evaluating eptinezumab for preventive treatment of chronic migraine in a predominantly Asian patient population. The trial addresses a critical unmet need, as migraine-specific treat...
